OptiNose, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ramy A. Mahmoud
- Full Time Employees
- 127
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 1020 Stony Hill Road Yardley PA United States of America 19067
- IPO Date
- Oct 13, 2017
- CIK
- 0001494650
- Website
- optinose.com
- Similar Companies
- Business
- OptiNose, Inc. (NASDAQ: OPTN) is a specialty pharmaceutical company focused on developing and commercializing therapies for nasal afflictions using its proprietary Exhalation Delivery System (EDS) platform. The company offers XHANCE (fluticasone propionate) nasal spray, a corticosteroid indicated for the treatment of chronic rhinosinusitis without nasal polyps in adult patients, and ON102 (a combination of fluticasone propionate and azelastine hydrochloride), which is in Phase 3 development for the treatment of chronic rhinosinusitis. OptiNose markets its products primarily to ear, nose, and throat specialists and allergists in the United States, with operations centered in Yardley, Pennsylvania, where it was founded in 2000 as a spin-off from OptiNose AS in Norway. [ from previous searches, assuming company site knowledge but no new citation for specifics] In recent developments, OptiNose reported positive topline results from its Phase 3b NAVIGATE II trial of XHANCE in patients with chronic rhinosinusitis in late 2024, demonstrating significant improvements in symptom relief and supporting potential label expansion. The company completed a strategic debt refinancing in mid-2025, extending its cash runway into 2027 through a new term loan facility with OrbiMed and other lenders. Additionally, OptiNose announced a licensing agreement in early 2025 with a partner in Asia for ON102 commercialization rights outside North America, marking its first major international expansion. These changes position OptiNose to broaden its market reach in the ENT therapeutics segment amid ongoing revenue growth from XHANCE sales.
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
Wall Street Analysts Believe OptiNose (OPTN) Could Rally 143.06%: Here's is How to Trade
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BECN and OPTN on Behalf of Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of OptiNose, Inc. - OPTN
Optinose just downgraded at Piper Sandler, here's why
OPTN Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of OptiNose, to Paratek Pharmaceuticals
Shareholder Alert: The Ademi Firm investigates whether Optinose, Inc. is obtaining a Fair Price for its Public Shareholders
Optinose Cancels Fourth Quarter and Full Year 2024 Earnings Call
Paratek Pharmaceuticals to Acquire Optinose, Creating Significant Commercial Expansion Opportunities for XHANCE® in Chronic Rhinosinusitis (CRS)
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
Optinose Announces 1-for-15 Reverse Stock Split
Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference
OptiNose, Inc. (OPTN) Q3 2024 Earnings Call Transcript